Tuesday, 17 November 2026European Markets

ULTIMOVACS Stock Is 21% Up In The Last 10 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of ULTIMOVACS (Oslo Børs All-share Index_GI: ULTI.OL) rose by a staggering 21.16% in 10 sessions from $110.6 to $134.00 at 13:44 EST on Tuesday, after three consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is rising 0.84% to $1,377.27, after successive sessions in a row of losses.

About ULTIMOVACS

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ULTIMOVACS has a trailing twelve months EPS of $-3.98.

Volatility

ULTIMOVACS's last week, last month's, and last quarter's current intraday variation average was 2.18%, 0.84%, and 2.72%.

ULTIMOVACS's highest amplitude of average volatility was 2.18% (last week), 2.05% (last month), and 2.72% (last quarter).

More news about ULTIMOVACS (ULTI.OL).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 7 Feb 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›